Patent thickets arent just a legal nuisancetheyre a market strategy. And if youre a biotech, pharma, or generic company trying to launch into a crowded therapeutic space, the real question isnt Can we win? Its Can we sequence our moves so the thicket c…

Blockbuster drugs dont just have patentsthey have recipes. And if youre trying to design around them, the real battleground is often not the active ingredient, but the formulation.
In the race to bring a next-best version to market, many teams focus na…

Pharma boards dont just inherit IP riskthey govern it.
In the last decade, patent litigation has evolved from a legal tail risk into a board-level operating variable. The question for todays executives isnt whether disputes will arise. Its whether lead…

Designing Around Formulation Patents: The Generic Developers Playbook (and Why Its Getting Harder)
In generic drug development, the fastest path to market is rarely a straight line. Its a mazeone where the walls arent just clinical, manufacturing, or r…

Pharma forensics is having a momentand its not just for patent attorneys.
In a market where formulation sounds like a technical footnote, the smartest players are treating it like a strategic map. The difference between winning and losing often isnt th…

Generic developers dont lose to bad luck. They lose to moats.
In pharma, the moat isnt always the headline patent everyone cites in investor decks. Sometimes its the secondary layerformulation tweaks, specific salt forms, polymorphs, controlled-relea…

Patent cliffs arent just legal eventstheyre operational earthquakes.
If youre running a pharma supply chain, procurement function, or manufacturing network, the patent cliff conversation cant stay in the courtroom. The real question is: Are you ready…

Most prior art searches miss the real story.
In patent work, weve all seen it: a search turns up the obviouskeywords match, citations line up, and the examiner (or opposing counsel) says, Case closed. But in chemical and biologic patents, the truth i…

Most pharma teams don’t lose to “bad science.” They lose to bad IP strategy.
If you’re building a next-generation product—or even just trying to extend a franchise—your biggest risk isn’t the molecule. It’s the formulation patent you didn’t plan for….

Formulation Forensics: The Hidden Clues in Drug Patent Claims (and Why They Matter to Investors)
Most people read drug patents like legal documents.
Smart investors read them like investigative reports.
Because buried in the fine printespecially in for…